Last reviewed · How we verify
EP395
At a glance
| Generic name | EP395 |
|---|---|
| Sponsor | EpiEndo Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial Investigating the Effects of EP395 Following an Inhaled Endotoxin Challenge in Healthy Adults (PHASE1)
- Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin (PHASE1)
- Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD (PHASE2)
- Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults (PHASE1)
- Single and Multiple Ascending Dose Study With EP395 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EP395 CI brief — competitive landscape report
- EP395 updates RSS · CI watch RSS
- EpiEndo Pharmaceuticals portfolio CI